| 1. |
-
- 2019
-
Journal article (peer-reviewed)
|
|
| 2. |
- Berntorp, Erik, et al.
(author)
-
The first Team Haemophilia Education meeting, 2015, Amsterdam, The Netherlands
- 2016
-
In: European Journal of Haematology. - : Wiley. - 0902-4441. ; 97, s. 3-18
-
Journal article (peer-reviewed)abstract
- Haemophilia remains a complex disorder to diagnose and manage, requiring close cooperation between multidisciplinary healthcare professionals. There are still many unmet challenges in haemophilia care. The first Team Haemophilia Education (THE) meeting, held on 7–8 May 2015 in Amsterdam, The Netherlands, aimed to promote the optimal care of haemophilia patients through education of the multidisciplinary treatment team. This was achieved by reviewing the latest developments in haemophilia management, considering how these can be implemented in the clinic to improve patient care and providing a platform for networking and debate for all haemophilia treatment team members. Haemophilia treatment centres from several countries were asked to complete a premeeting online questionnaire to establish the biggest challenges that they face when managing patients. The concerns expressed were used to develop the agenda, which comprised a combination of formal presentations, case studies and informal workshops covering such topics as pharmacokinetics, laboratory assays and tailoring of treatment to individual patients. This report is a summary of the key developments in haemophilia care presented by various investigators and healthcare professionals at THE meeting 2015.
|
|
| 3. |
- Engert, Andreas, et al.
(author)
-
The European Hematology Association Roadmap for European Hematology Research : a consensus document
- 2016
-
In: Haematologica. - Pavia, Italy : Ferrata Storti Foundation (Haematologica). - 0390-6078 .- 1592-8721. ; 101:2, s. 115-208
-
Journal article (peer-reviewed)abstract
- The European Hematology Association (EHA) Roadmap for European Hematology Research highlights major achievements in diagnosis and treatment of blood disorders and identifies the greatest unmet clinical and scientific needs in those areas to enable better funded, more focused European hematology research. Initiated by the EHA, around 300 experts contributed to the consensus document, which will help European policy makers, research funders, research organizations, researchers, and patient groups make better informed decisions on hematology research. It also aims to raise public awareness of the burden of blood disorders on European society, which purely in economic terms is estimated at (sic)23 billion per year, a level of cost that is not matched in current European hematology research funding. In recent decades, hematology research has improved our fundamental understanding of the biology of blood disorders, and has improved diagnostics and treatments, sometimes in revolutionary ways. This progress highlights the potential of focused basic research programs such as this EHA Roadmap. The EHA Roadmap identifies nine 'sections' in hematology: normal hematopoiesis, malignant lymphoid and myeloid diseases, anemias and related diseases, platelet disorders, blood coagulation and hemostatic disorders, transfusion medicine, infections in hematology, and hematopoietic stem cell transplantation. These sections span 60 smaller groups of diseases or disorders. The EHA Roadmap identifies priorities and needs across the field of hematology, including those to develop targeted therapies based on genomic profiling and chemical biology, to eradicate minimal residual malignant disease, and to develop cellular immunotherapies, combination treatments, gene therapies, hematopoietic stem cell treatments, and treatments that are better tolerated by elderly patients.
|
|
| 4. |
- Hosseini, Keyvan, et al.
(author)
-
E-bike to the future : Scalability, emission-saving, and eco-efficiency assessment of shared electric mobility hubs
- 2024
-
In: Transportation Research Part D. - : Elsevier. - 1361-9209 .- 1879-2340. ; 133
-
Journal article (peer-reviewed)abstract
- In car-dominated urban areas, shared electric micro-mobility offers a sustainable alternative to decarbonise and reshape mobility paradigms. This paper presents a comprehensive framework for evaluating Dublin's e-bike sharing system, comprising 12 stations (eHUBs). Using six months of real-world riding data, it employs data envelopment analysis to assess the eco-efficiency of each eHUB in utilising nearby infrastructure, population in the catchment area, and location to achieve desired economic, social, and environmental outputs. Results indicate an upward trajectory for the system's eco-efficiency. The returns-to-scale analysis provides insights into the system's scalability, suggesting that expanding the e-bike sharing system, along with infrastructural enhancements, would significantly increase ridership. Analysing decarbonisation, usage patterns, and spatial factors of eHUBs reveals the substantial potential of shared e-bikes if optimally used. The research highlights the need to reevaluate car-centric policies in favour of more inclusive and environmentally sustainable alternatives and proposes actionable policy recommendations to achieve this transformation.
|
|
| 5. |
- Skinner, Mark W., et al.
(author)
-
Achieving the unimaginable : Health equity in haemophilia
- 2020
-
In: Haemophilia. - : Wiley. - 1351-8216 .- 1365-2516. ; 26:1, s. 17-24
-
Research review (peer-reviewed)abstract
- Historically, treatment based on the availability of clotting factor replacement has resulted in an arcane guideline for the correction of factor deficiencies in people with haemophilia (PwH). While all other disease entities seek to restore function to a normal level, PwH are restricted to factor nadirs still equivalent to mild or moderate disease, resulting in continued risk of bleeding. A new treatment paradigm is needed based on the defined needs of PwH. A treatment model was developed by a panel of haemophilia providers, patient advocates and health economists to establish specific treatment milestones and targeted outcomes. The panel defined a series of treatment milestones to characterize the activity and outcomes linked to level of factor deficiency correction. All agreed that the ultimate goal should be ‘functional cure’ and ‘health equity’. Seven levels to achieving a functional cure were identified, (a) Sustain life; (b) Minimal joint impairment; (c) Freedom from any spontaneous bleeds; (d) Attainment of ‘normal’ mobility; (e) Able to sustain minor trauma without additional intervention; (f) Ability to sustain major surgery or trauma; and (g) Normal haemostasis. A parallel set of patient-reported outcomes to achieve health equity was identified. These guidelines are now comparable with other disorders where the goal is to replace missing proteins to attain normal activity levels. As we are no longer limited by plasma supply due to the manufacture of recombinant factors, mimetics, and the early success of gene therapy, health equity is now achievable.
|
|
